Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade-why it could be a novel paradigm?

Johny Nicolas, Ridhima Goel, Bimmer Claessen, Roxana Mehran

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Fingerprint

Dive into the research topics of 'Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade-why it could be a novel paradigm?'. Together they form a unique fingerprint.

Medicine & Life Sciences